c 9253-6T > c REV3L: A novel marker of poor prognosis in Myelodysplastic syndrome

Oliveira, Roberta Taiane G. de; França, Ivo Gabriel. F; L.R. Junior, Howard; Riello, Giovanna B. C; Borges, Daniela de Paula; Cavalcante, Gabrielle Melo; Magalhães, Silvia M. M; Pinheiro, Ronald F.
Hematol., Transfus. Cell Ther. (Impr.) ; 43(3): 377-381, July-Sept. 2021. tab, ilus
Artículo en Inglés | LILACS | ID: biblio-1346260

Documentos relacionados

  1. Co-mutation landscape and clinical significance of RAS pathway related gene mutations in patients with myelodysplastic syndrome.
  2. Myelodysplastic syndromes, thy name is heterogeneity.
  3. [Molecular international prognostic scoring system for myelodysplastic syndromes].
  4. Distinct genetic landscapes and their clinical implications in younger and older patients with myelodysplastic syndromes.
  5. A Lower Frequency of Spliceosome Mutations Distinguishes Clonal Cytopenias of Undetermined Significance From Low-Risk Myelodysplastic Syndromes, Despite Inherent Similarities in Genomic, Laboratory, and Clinical Features.
  6. Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort.
  7. Somatic mutations show no clear association with red blood cell or human leukocyte antigen alloimmunization in de novo or therapy-related myelodysplastic syndrome.
  8. The role of genetic factors in pediatric myelodysplastic syndromes with different outcomes.
  9. MYELODYSPLASTIC SYNDROME: DIAGNOSIS, TREATMENT AND PROGNOSIS (LITERATURE REVIEW).
  10. [Future perspectives in Myelodysplastic Syndrome].